Cargando…

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Banini, Marco, Salvestrini, Viola, Vultaggio, Alessandra, Perlato, Margherita, Mecheri, Valentina, Cerbai, Cecilia, Scotti, Vieri, Matucci, Andrea, Mangoni, Monica, Livi, Lorenzo, Bonomo, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378378/
https://www.ncbi.nlm.nih.gov/pubmed/37504351
http://dx.doi.org/10.3390/curroncol30070491
_version_ 1785079750891405312
author Banini, Marco
Salvestrini, Viola
Vultaggio, Alessandra
Perlato, Margherita
Mecheri, Valentina
Cerbai, Cecilia
Scotti, Vieri
Matucci, Andrea
Mangoni, Monica
Livi, Lorenzo
Bonomo, Pierluigi
author_facet Banini, Marco
Salvestrini, Viola
Vultaggio, Alessandra
Perlato, Margherita
Mecheri, Valentina
Cerbai, Cecilia
Scotti, Vieri
Matucci, Andrea
Mangoni, Monica
Livi, Lorenzo
Bonomo, Pierluigi
author_sort Banini, Marco
collection PubMed
description Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC). Its excellent efficacy outcomes are achieved due to its good tolerability profile. The drug-related hypersensitivity reaction (HSR) is a well-known issue in oncology, but it is rarely reported in respect to immune checkpoint inhibitors. Cemiplimab is among the agents with the best infusion tolerability profiles. Clinical practice guidelines in this field are lacking. Results: We report on the successful management of a severe infusion reaction induced by Cemiplimab in a patient with cSCC based on a desensitization protocol, which led to adequate treatment delivery and prolonged clinical benefit. A review of the available literature on HSR rates and its management with ICIs, and on drug desensitization (DD) protocols and their efficacy, was conducted to highlight the limited knowledge on this topic and its importance. Conclusion: Our experience highlights the need for a DD protocol in order to improve the treatment of HSRs, particularly when elicited by an immunotherapy agent, preventing treatment discontinuation and preserving its efficacy.
format Online
Article
Text
id pubmed-10378378
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103783782023-07-29 Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review Banini, Marco Salvestrini, Viola Vultaggio, Alessandra Perlato, Margherita Mecheri, Valentina Cerbai, Cecilia Scotti, Vieri Matucci, Andrea Mangoni, Monica Livi, Lorenzo Bonomo, Pierluigi Curr Oncol Case Report Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC). Its excellent efficacy outcomes are achieved due to its good tolerability profile. The drug-related hypersensitivity reaction (HSR) is a well-known issue in oncology, but it is rarely reported in respect to immune checkpoint inhibitors. Cemiplimab is among the agents with the best infusion tolerability profiles. Clinical practice guidelines in this field are lacking. Results: We report on the successful management of a severe infusion reaction induced by Cemiplimab in a patient with cSCC based on a desensitization protocol, which led to adequate treatment delivery and prolonged clinical benefit. A review of the available literature on HSR rates and its management with ICIs, and on drug desensitization (DD) protocols and their efficacy, was conducted to highlight the limited knowledge on this topic and its importance. Conclusion: Our experience highlights the need for a DD protocol in order to improve the treatment of HSRs, particularly when elicited by an immunotherapy agent, preventing treatment discontinuation and preserving its efficacy. MDPI 2023-07-14 /pmc/articles/PMC10378378/ /pubmed/37504351 http://dx.doi.org/10.3390/curroncol30070491 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Banini, Marco
Salvestrini, Viola
Vultaggio, Alessandra
Perlato, Margherita
Mecheri, Valentina
Cerbai, Cecilia
Scotti, Vieri
Matucci, Andrea
Mangoni, Monica
Livi, Lorenzo
Bonomo, Pierluigi
Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
title Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
title_full Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
title_fullStr Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
title_full_unstemmed Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
title_short Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
title_sort desensitization protocol for cemiplimab-related infusion reaction in cutaneous squamous cell carcinoma: a case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378378/
https://www.ncbi.nlm.nih.gov/pubmed/37504351
http://dx.doi.org/10.3390/curroncol30070491
work_keys_str_mv AT baninimarco desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT salvestriniviola desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT vultaggioalessandra desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT perlatomargherita desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT mecherivalentina desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT cerbaicecilia desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT scottivieri desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT matucciandrea desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT mangonimonica desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT livilorenzo desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview
AT bonomopierluigi desensitizationprotocolforcemiplimabrelatedinfusionreactionincutaneoussquamouscellcarcinomaacasereportandliteraturereview